S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:SCYX

SCYNEXIS (SCYX) Stock Price, News & Analysis

$1.42
+0.04 (+2.89%)
(As of 03/27/2024 ET)
Today's Range
$1.40
$1.46
50-Day Range
$1.39
$2.14
52-Week Range
$1.35
$3.87
Volume
107,777 shs
Average Volume
219,847 shs
Market Capitalization
$53.02 million
P/E Ratio
1.00
Dividend Yield
N/A
Price Target
$12.25

SCYNEXIS MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
759.6% Upside
$12.25 Price Target
Short Interest
Healthy
2.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.23mentions of SCYNEXIS in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-78.46%
From $1.95 to $0.42 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.20 out of 5 stars

Medical Sector

351st out of 939 stocks

Pharmaceutical Preparations Industry

156th out of 435 stocks

SCYX stock logo

About SCYNEXIS Stock (NASDAQ:SCYX)

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYX Stock Price History

SCYX Stock News Headlines

SCYNEXIS (NASDAQ:SCYX) Downgraded by StockNews.com to "Hold"
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
SCYNEXIS Stock (NASDAQ:SCYX) Insider Trades
Promising Antifungal Drug Developments Bolster Buy Rating for SCYNEXIS
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Scynexis 48 Hour Deadline Alert
Scynexis Deadline Reminder
SCYNEXIS Inc SCYX
See More Headlines
Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SCYX
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.25
High Stock Price Target
$15.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+759.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-62,810,000.00
Pretax Margin
53.14%

Debt

Sales & Book Value

Annual Sales
$5.09 million
Book Value
$0.10 per share

Miscellaneous

Free Float
35,571,000
Market Cap
$53.02 million
Optionable
Optionable
Beta
1.59
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. David Gonzalez Angulo M.D. (Age 59)
    CEO, President & Director
    Comp: $631.69k
  • Mr. Scott Sukenick J.D. (Age 46)
    Chief Legal Officer & Corporate Secretary
    Comp: $542.05k
  • Mr. Ivor Macleod CPA (Age 63)
    M.B.A., Chief Financial Officer
  • Debbie Etchison
    Executive Director of Communications
  • Ms. Daniella Gigante
    Vice President of Human Resources & Information Technology

SCYX Stock Analysis - Frequently Asked Questions

Should I buy or sell SCYNEXIS stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYX shares.
View SCYX analyst ratings
or view top-rated stocks.

What is SCYNEXIS's stock price target for 2024?

3 Wall Street research analysts have issued 12 month target prices for SCYNEXIS's stock. Their SCYX share price targets range from $9.00 to $15.00. On average, they expect the company's share price to reach $12.25 in the next year. This suggests a possible upside of 759.6% from the stock's current price.
View analysts price targets for SCYX
or view top-rated stocks among Wall Street analysts.

How have SCYX shares performed in 2024?

SCYNEXIS's stock was trading at $2.23 at the beginning of 2024. Since then, SCYX stock has decreased by 36.1% and is now trading at $1.4250.
View the best growth stocks for 2024 here
.

When is SCYNEXIS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our SCYX earnings forecast
.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.73. The company had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.50 million. SCYNEXIS had a net margin of 53.14% and a trailing twelve-month return on equity of 238.09%. During the same quarter in the prior year, the company earned ($0.28) earnings per share.

When did SCYNEXIS's stock split?

SCYNEXIS shares reverse split on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of SCYNEXIS own?
Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by many different retail and institutional investors. Top institutional shareholders include Kingdon Capital Management L.L.C. (6.01%), Vanguard Group Inc. (4.19%), Vanguard Group Inc. (4.19%), Avidity Partners Management LP (3.89%), Stonepine Capital Management LLC (3.64%) and Decheng Capital LLC (1.49%). Insiders that own company stock include Marco Taglietti and Scott Sukenick.
View institutional ownership trends
.

How do I buy shares of SCYNEXIS?

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SCYX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners